About mecasermin
Recombinant human insulin-like growth factor 1
Used for
- Treats severe primary insulin-like growth factor 1 deficiency in children and adolescents with growth failure.
Usual adult dose
Not approved for routine adult use.
Usual dose in children
Usually 0.04–0.08 mg/kg under the skin twice daily; may increase gradually to 0.12 mg/kg twice daily.
Common side effects
- Low blood sugar
- Injection-site reactions
- Enlarged tonsils or adenoids
- Headache
Important warnings
- Give shortly before or after a meal; skip the dose if a meal is missed.
- Low blood sugar can cause seizures or loss of consciousness.
- May cause increased pressure in the brain or enlarged tonsils and adenoids.
- Do not use for growth failure caused by growth hormone deficiency or malnutrition.
Pregnancy
Human pregnancy data are limited; use requires careful assessment of potential benefits and risks.
Breastfeeding
It is unknown whether mecasermin passes into breast milk; effects on nursing infants are uncertain.
Interactions
- Insulin and other diabetes medicines may increase the risk of low blood sugar.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.